Pfizer (PFE) EVP Fonseca settles 56,888 SARs with tax share withholdings

Rhea-AI Filing Summary

Pfizer Inc executive Lidia Fonseca reported derivative and related share transactions tied to stock appreciation rights (SARs). On February 25, 2026, she exercised 56,888 SARs, receiving 56,888 shares of Pfizer common stock at an exercise price of $33.82 per share.

To cover taxes and exercise costs from this earn-out, 1,058 shares and 54,066 shares of common stock were withheld in tax-withholding dispositions at prices of $27.09 and $26.92 per share, respectively. After these transactions, her directly owned Pfizer common stock position was 46,455 shares, and the exercised SARs balance was reduced to zero. Footnotes specify these events arise from the earn-out and settlement terms of the SARs, which use a 20-day average closing price of Pfizer common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fonseca Lidia

(Last) (First) (Middle)

66 HUDSON BOULEVARD EAST

ATTN: CORPORATE SECRETARY

(Street)

NEW YORK NY 10001-2192

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PFIZER INC [ PFE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Vice President

3. Date of Earliest Transaction (Month/Day/Year)
02/25/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/25/2026		M		56,888(1)	A	$33.82	101,579	D
Common Stock	02/25/2026		F		1,058(2)	D	$27.09	100,521	D
Common Stock	02/25/2026		F		54,066(3)	D	$26.92(4)	46,455	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Appreciation Rights	$33.82	02/25/2026		M			56,888	02/25/2026	02/25/2026	Common Stock	56,888	$0.0000	0.0000	D

Explanation of Responses:

1. The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).

2. The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.

3. The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).

4. Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.

	/s/ Shanice A. Reid, by power of atty, for Lidia Fonseca	02/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Pfizer (PFE) executive Lidia Fonseca report in this Form 4?

Pfizer executive Lidia Fonseca reported exercising stock appreciation rights into 56,888 Pfizer common shares, followed by share withholdings for taxes and exercise costs. These transactions are part of an earn-out and did not reflect open-market buying or selling.

How many Pfizer (PFE) shares did Lidia Fonseca acquire through the SAR exercise?

She acquired 56,888 Pfizer common shares via the exercise of stock appreciation rights. The transaction was recorded at an exercise price of $33.82 per share, converting derivative compensation into directly held Pfizer stock on the reported date.

Why were some Pfizer (PFE) shares disposed of in Lidia Fonseca’s Form 4?

Shares were withheld to satisfy tax obligations and exercise price payments related to the SAR earn-out. Specifically, 1,058 and 54,066 shares of Pfizer common stock were used in tax-withholding dispositions, rather than sold as discretionary open-market transactions.

What is Lidia Fonseca’s Pfizer (PFE) share ownership after these Form 4 transactions?

After the reported SAR exercise and share withholdings, Lidia Fonseca directly owned 46,455 shares of Pfizer common stock. The stock appreciation rights position involved in this earn-out was reduced to zero following the settlement and related tax-withholding transactions.

How were the stock appreciation rights for Pfizer (PFE) valued in this Form 4?

The settlement of the stock appreciation rights used a 20-day average of Pfizer’s closing stock prices ending on the settlement date. This averaging method determined the value applied when converting the SARs into Pfizer common shares for the executive.